CanaQuest Medical Corp., a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), announced its new partnership with the Canadian Cannabis Dispute Resolution Centre (CCDRC), a national organization that has developed cannabis-related education and training programs, both domestically and internationally, to assist different levels of government, the private sector, industry-specific organizations and associations.
The CCDRC/CanaQuest partnership will serve to raise global awareness. The common theme of all education relates to conflict resolution, which can be mitigated through education. A critical component of the partnership will be its focus on promoting scientifically backed evidence, pre-clinical data and published research papers of Dr. Steven Laviolette and his 13-person team at Western University in Canada.
For the past 20 years, Dr. Laviolette and team have studied the effects of cannabinoids on mental health and wellness. Their research focuses on using cannabinoids for the development of novel pharmacotherapies to address anxiety, depression, addiction, schizophrenia and Post Traumatic Stress Disorder (PTSD).
Treena Reilkoff, a Trauma Informed Mediator and Facilitator with the CCDRC stated, “We are pleased to have the opportunity to collaborate with CanaQuest. Our common goal is the recognition that medicinal cannabis is an alternative treatment to traditional pharmaceuticals and through education about the practicality and safety of medicinal cannabis, barriers and stigmas are reduced. The CCDRC is pleased to provide education and consulting services to help prevent cannabis-related workplace conflicts from escalating.”
Paul Ramsay, CanaQuest Co-founder and President, added, “Our joint recognition of the importance of education and of people being able to have self-determination in their choices of prescriptions are the key drivers of this partnership.“
CanaQuest Medical Corp is a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade). The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist, who has 20 years of research experience in the field of mental health and cannabinoids and oversees a team of 13 scientists at Western University.
As well, CanaQuest will be selling both products through its wholly owned subsidiary, ADC BioMedical Corp, which was awarded a Cannabis Medical Sales, Import/Export License, from Health Canada under the Cannabis Act. Licenced GMP Contract Manufacturers in Canada and the USA, capable of formulating, processing, and packaging, have been selected for production and distribution. The Company won the Go Global Awards, 2019, “Business of the Year – Category of Life Science,” presented by the International Trade Council.
The Canadian Cannabis Dispute Resolution Centre is a national organization of Canadian alternative dispute resolution specialists and conflict resolution trainers with expertise in cannabis law, policy and dispute resolution. The CCDRC aspires to be an innovator in identifying practical and pre-emptive solutions to cannabis-related disputes.